Opportunities and Challenges in Multiple Myeloma Treatment and Management
A special issue of Hematology Reports (ISSN 2038-8330).
Deadline for manuscript submissions: closed (30 May 2023) | Viewed by 2052
Special Issue Editors
Interests: acute lymphoblastic leukemia; acute myeloid leukemia; myelodysplastic syndromes; multiple myeloma and MGUS; non-Hodgkin and Hodgkin lymphoma
Special Issues, Collections and Topics in MDPI journals
Interests: leukemias; lymphomas; acute leukemia; chronic myeloid leukemia
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Multiple myeloma (MM) is a hematological malignancy characterized by a high propensity for recurrence and drug resistance. A wide range of genetic and epigenetic abnormalities have been implicated in the pathogenesis of this cancer, ultimately affecting the growth, survival and drug sensitivity of multiple myeloma cells.
Although many therapeutic agents have been developed to improve the depth and duration of response and prolong patient survival, the management of multiple myeloma remains challenging due to the eventual emergence of drug-resistant clones and often imminent relapse. These events have prompted continued research to identify new molecular lesions and therapeutic targets, with the ultimate goal of finding a cure for multiple myeloma.
Therefore, this special issue focuses on the tumor microenvironment and mechanisms of deterioration, i.e. drug resistance, proliferative signaling, immune evasion, etc., which are involved in the aggressive disease behavior of refractory MM, to better manage those that develop into new tumors. treatment strategy.
Dr. Claudio Cerchione
Dr. Giovanni Martinelli
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Hematology Reports is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple myeloma
- hematological malignancy
- drug resistance
- tumor microenvironment
